bevacizumab + sunitinib

This combination therapy regimen consists of bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), and sunitinib, a multi-targeted small molecule tyrosine kinase inhibitor. Investigated primarily by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of metastatic renal cell carcinoma (mRCC), the rationale was to provide continuous antiangiogenic blockade by using bevacizumab to prevent rebound angiogenesis during the standard two-week rest period of sunitinib. However, clinical trials (Phase I/II) revealed significant overlapping toxicities, including severe hypertension, hematologic issues, and vascular complications, leading to the discontinuation of further development of this specific combination at the tested dose levels.

Other names

Bevacizumab and SunitinibSunitinib and Bevacizumab